Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Compass Therapeutics, Inc.
NASDAQ:CMPXHealthcare · Biotechnology
-5.05%$0.7610
AH Close$0.7697+1.14%vs close
AH Close$0.7697+1.14%vs close
Mkt Cap$137.05M
Float115.71M
O/S180.09M
Inst Own92.0%
SI34.9%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$66.49M
Total Assets$219.59M
Free Cash Flow-$49.17M
Debt & Equity
Debt 5%
Equity 95%
Total Debt$9.83M
Total Equity$196.79M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in CMPX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$219.59M
Liabilities$22.8M
Accounts Receivable$0
Accounts Payable$1.58M
Inventory$0
PP&E (Net)$9.2M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2020-03-31 | 2019-03-31 |
| Revenue | $0 | $850K | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.47M | $0 | $0 | $0 | $0 | $0 | $0 | $1.92M |
| Gross Profit | -$1.47M | $850K | $0 | $0 | $0 | $0 | $0 | -$1.92M |
| Gross Margin | - | 100.0% | - | - | - | - | - | - |
| Research and Development | $55.97M | $42.34M | $38.12M | $30M | $20.34M | $14.9M | $22.45M | $27.09M |
| Selling, General, and Administrative | $16.87M | $15.13M | $12.24M | $11.66M | $10.93M | $12.91M | $11.6M | $11.22M |
| Other | -$1.47M | $0 | $0 | $0 | $50.62M | $0 | $0 | $0 |
| Total Operating Expenses | $71.37M | $57.48M | $50.36M | $41.66M | $81.88M | $27.81M | $34.05M | $38.31M |
| Operating Income (EBIT) | -$72.84M | -$56.63M | -$50.36M | -$41.66M | -$81.88M | -$27.81M | -$34.05M | -$38.31M |
| Operating Margin | - | -6661.8% | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $2.36M | $370K | $908K | $1.23M | $767K |
| Interest Income | $6.35M | $7.3M | $7.9M | $2.36M | $29K | $88K | $743K | $663K |
| Other Income (Expense) | $6.35M | $7.25M | $7.87M | $2.43M | -$299K | -$1.66M | -$601K | $233K |
| Income Before Tax (EBT) | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.47M | -$34.65M | -$38.18M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $32K | $91K | $103K |
| Net Income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.5M | -$34.74M | -$38.29M |
| Net Income Margin | - | -5808.8% | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -0.42 | -0.36 | -0.33 | -0.35 | -1.31 | -0.52 | -0.67 | -7.66 |
| Diluted EPS | -0.42 | -0.36 | -0.33 | -0.35 | -1.31 | -0.52 | -0.67 | -7.66 |
| Weighted Average OS | 157.69M | 137.11M | 127.03M | 105.19M | 62.87M | 56.22M | 52.11M | 5.00M |
| EBITDA | -$65.02M | -$47.62M | -$40.6M | -$34.96M | -$80.19M | -$25.41M | -$31.93M | -$35.73M |
| EBITDA Margin | - | -5602.6% | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2020-03-31 | 2019-03-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $30.64M | $43.48M | $24.23M | $34.95M | $144.51M | $47.08M | $25.3M | $57.51M |
| Short-Term Investments | $178.26M | $83.24M | $128.23M | $151.66M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $208.91M | $126.72M | $152.46M | $186.61M | $144.51M | $47.08M | $25.3M | $57.51M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $913K | $6.03M | $1.42M | $8.18M | $0 | $0 | $0 | $1.37M |
| Total Current Assets | $209.82M | $132.75M | $153.88M | $194.79M | $147.1M | $50.2M | $26.24M | $58.88M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $9.2M | $7.08M | $2.67M | $4.53M | $6.33M | $1.13M | $3.75M | $5.37M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $262K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $568K | $568K | $320K | $320K | $320K | $583K | $392K | $115K |
| Total Long-Term Assets | $9.77M | $7.65M | $2.99M | $4.85M | $6.65M | $1.71M | $4.14M | $5.74M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $219.59M | $140.4M | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M | $64.63M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $1.58M | $2.25M | $4.09M | $3.38M | $867K | $1.06M | $629K | $1.73M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $7.47M | $5.58M | $3.69M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $554K | $519K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $519K |
| Other Current Liabilities | $2.68M | $2.79M | $1.94M | $1.56M | $1.6M | $976K | $2.25M | $2.53M |
| Total Current Liabilities | $13.97M | $8.87M | $7.8M | $16.17M | $10.63M | $10.1M | $9.82M | $8.46M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $8.83M | $0 | $0 | $0 | $0 | $1.87M | $9.29M | $11.06M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $1K | $0 | $0 | $0 | $0 | $129.87M | $129.87M |
| Total Long-Term Liabilities | $8.83M | $6.3M | $536K | $1.84M | $3.05M | $1.87M | $139.16M | $140.93M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $22.8M | $15.17M | $8.34M | $18.01M | $13.68M | $11.97M | $148.98M | $149.4M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $129.87M |
| Common Stock | $18K | $13K | $13K | $13K | $10K | $5K | $1K | $2.39M |
| Retained Earnings | -$431.17M | -$364.68M | -$315.31M | -$272.81M | -$233.59M | -$151.41M | -$121.91M | -$87.16M |
| Comprehensive Income & Other | $280K | $210K | $37K | -$302K | $0 | $0 | $0 | -$4.1M |
| Other Stockholders' Equity | $627.95M | $489.9M | $463.83M | $454.44M | $373.66M | $191.35M | $3.3M | $0 |
| Total Equity | $196.79M | $125.23M | $148.54M | $181.64M | $140.08M | $39.95M | -$118.6M | -$84.77M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $219.59M | $140.4M | $156.88M | $199.65M | $153.76M | $51.91M | $30.38M | $64.63M |
| Supplementary Data | ||||||||
| Total Debt | $9.83M | $6.63M | $1.73M | $2.94M | $4.04M | $9.33M | $14.87M | $14.75M |
| Net Debt | -$20.81M | -$36.85M | -$22.5M | -$32.01M | -$140.48M | -$37.74M | -$10.43M | -$42.76M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2020-03-31 | 2019-03-31 |
| Operating Activities | ||||||||
| Net Income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M | -$29.5M | -$34.74M | -$38.29M |
| Depreciation & Amortization | $1.47M | $1.75M | $1.89M | $1.9M | $1.62M | $2.4M | $2.12M | $1.92M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $837K | $109K | -$261K |
| Stock-Based Compensation | $8.37M | $8.56M | $6.12M | $5.33M | $4.03M | $4.02M | $915K | $656K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$664K | -$1.84M | $708K | $2.52M | -$194K | $432K | -$1.1M | $992K |
| Other Working Capital | $9.84M | -$2.3M | -$3.62M | -$3.78M | $6.44M | -$4.03M | $844K | $1.18M |
| Total Working Capital Change | $9.18M | -$4.14M | -$2.91M | -$1.26M | $6.25M | -$3.6M | -$257K | $2.17M |
| Other Non-Cash Items | -$1.67M | -$1.65M | -$3.23M | -$871K | $50.62M | -$960K | $116K | $121K |
| Net Cash from Operating | -$49.14M | -$44.85M | -$40.62M | -$34.13M | -$19.67M | -$26.8M | -$31.74M | -$33.68M |
| Investing Activities | ||||||||
| Capital Expenditures | -$25K | -$44K | -$30K | -$212K | -$1.57M | -$106K | -$466K | -$2.02M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $144K | $0 | $0 |
| Purchases of Investments | -$194.56M | -$88.16M | -$155.42M | -$200.12M | $0 | $0 | $0 | $0 |
| Sales of Investments | $101.28M | $134.97M | $182.41M | $48.95M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $176K | -$202K | $144 | $0 | $0 |
| Net Cash from Investing | -$93.31M | $46.77M | $26.96M | -$151.2M | -$1.77M | $38K | -$466K | -$2.02M |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | $9.38M | - | - | - |
| Common Stock Issuance | $130.64M | $18.11M | $3.09M | $0 | $128.27M | $60.48M | $0 | $49.08M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.03M | -$775K | -$159K | $75.76M | -$281K | -$6.32M | $38K | $64.03M |
| Net Cash from Financing | $129.61M | $17.34M | $2.94M | $75.76M | $118.61M | $48.54M | $38K | $64.03M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | -$38K | $0 |
| Net Change in Cash | -$12.84M | $19.25M | -$10.72M | -$109.57M | $97.17M | $21.77M | -$32.21M | $28.33M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$49.14M | -$44.85M | -$40.62M | -$34.13M | -$19.67M | -$26.8M | -$31.74M | -$33.68M |
| Capital Expenditure | -$25K | -$44K | -$30K | -$212K | -$1.57M | -$106K | -$466K | -$2.02M |
| Free Cash Flow | -$49.17M | -$44.9M | -$40.65M | -$34.34M | -$21.23M | -$26.91M | -$32.21M | -$35.7M |
| Cash at Beginning | $44.05M | $24.23M | $34.95M | $144.51M | $47.34M | $25.57M | $57.77M | $29.44M |
| Cash at End | $31.21M | $43.48M | $24.23M | $34.95M | $144.51M | $47.34M | $25.57M | $57.77M |